Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembre
Introduction and Objective: To determine the progression to liver fibrosis secondary to non-alcoholic fatty liver disease (NAFLD) by non-invasive methods in patients with Inflammatory Bowel Disease (IBD). Material and Methods: Descriptive, cross-sectional, and retrospective study. Variables analyzed...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S166526812200134X |
| _version_ | 1811320013578043392 |
|---|---|
| author | IE Severino-Ferreras LO Rodríguez-Muñoz JG Lopez-Gómez |
| author_facet | IE Severino-Ferreras LO Rodríguez-Muñoz JG Lopez-Gómez |
| author_sort | IE Severino-Ferreras |
| collection | DOAJ |
| description | Introduction and Objective: To determine the progression to liver fibrosis secondary to non-alcoholic fatty liver disease (NAFLD) by non-invasive methods in patients with Inflammatory Bowel Disease (IBD). Material and Methods: Descriptive, cross-sectional, and retrospective study. Variables analyzed: age, sex, type of IBD, treatment, Fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS). The SPSS version 25 program was used, with univariate analysis, 95% CI and significant P <0.05. Results: Of 125 patients, 88 (70.4%) had chronic nonspecific ulcerative colitis (UC) and 37 (29.6%) had Crohn's disease (CD). NAFLD was found in 20 patients (16%), with fibrosis in 20% (4 patients), as well as cirrhosis (20%) without statistical significance (Table 1). Grade F0-F2 (NFS<1.455) was more frequent in both groups, with no significant correlation with IBD. Ustekinumab correlated with NAFLD without fibrosis (P<0.05), while mesalazine correlated significantly with liver fibrosis (F3-F4). Discussion: NAFLD occurs in 50% of patients with IBD. The pathogenesis includes, on the one hand, the release of cytokines and adipokines that lead to increased inflammation and hepatic fibrosis and, on the other, altered intestinal permeability, with the consequent hepatic fatty infiltration. For its diagnosis, non-invasive tools were created, such as NFS and FIB-4, with the best predictive value for advanced liver fibrosis. Conclusions: The occurrence of NAFLD and progression to fibrosis were significantly correlated with the treatment of the underlying disease. Funding: The resources used in this study were from the hospital without any additional financing Declaration of interest: The authors declare no potential conflicts of interest. |
| first_indexed | 2024-04-13T12:52:03Z |
| format | Article |
| id | doaj.art-630597a898f641249ca0f34107785a7a |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-04-13T12:52:03Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-630597a898f641249ca0f34107785a7a2022-12-22T02:46:10ZengElsevierAnnals of Hepatology1665-26812022-12-0127100792Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembreIE Severino-Ferreras0LO Rodríguez-Muñoz1JG Lopez-Gómez2Department of Gastroenterology. National Medical Center “20 de Noviembre”, ISSSTE. Mexico City, MexicoDepartment of Gastroenterology. National Medical Center “20 de Noviembre”, ISSSTE. Mexico City, MexicoInflammatory Bowel Disease Clinic. National Medical Center “20 de Noviembre”, ISSSTE. Mexico City, MexicoIntroduction and Objective: To determine the progression to liver fibrosis secondary to non-alcoholic fatty liver disease (NAFLD) by non-invasive methods in patients with Inflammatory Bowel Disease (IBD). Material and Methods: Descriptive, cross-sectional, and retrospective study. Variables analyzed: age, sex, type of IBD, treatment, Fibrosis-4 (FIB-4) and NAFLD fibrosis score (NFS). The SPSS version 25 program was used, with univariate analysis, 95% CI and significant P <0.05. Results: Of 125 patients, 88 (70.4%) had chronic nonspecific ulcerative colitis (UC) and 37 (29.6%) had Crohn's disease (CD). NAFLD was found in 20 patients (16%), with fibrosis in 20% (4 patients), as well as cirrhosis (20%) without statistical significance (Table 1). Grade F0-F2 (NFS<1.455) was more frequent in both groups, with no significant correlation with IBD. Ustekinumab correlated with NAFLD without fibrosis (P<0.05), while mesalazine correlated significantly with liver fibrosis (F3-F4). Discussion: NAFLD occurs in 50% of patients with IBD. The pathogenesis includes, on the one hand, the release of cytokines and adipokines that lead to increased inflammation and hepatic fibrosis and, on the other, altered intestinal permeability, with the consequent hepatic fatty infiltration. For its diagnosis, non-invasive tools were created, such as NFS and FIB-4, with the best predictive value for advanced liver fibrosis. Conclusions: The occurrence of NAFLD and progression to fibrosis were significantly correlated with the treatment of the underlying disease. Funding: The resources used in this study were from the hospital without any additional financing Declaration of interest: The authors declare no potential conflicts of interest.http://www.sciencedirect.com/science/article/pii/S166526812200134X |
| spellingShingle | IE Severino-Ferreras LO Rodríguez-Muñoz JG Lopez-Gómez Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembre Annals of Hepatology |
| title | Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembre |
| title_full | Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembre |
| title_fullStr | Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembre |
| title_full_unstemmed | Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembre |
| title_short | Increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic, Centro Medico Nacional 20 de noviembre |
| title_sort | increase in liver fibrosis in patients with inflammatory bowel disease at the inflammatory bowel disease clinic centro medico nacional 20 de noviembre |
| url | http://www.sciencedirect.com/science/article/pii/S166526812200134X |
| work_keys_str_mv | AT ieseverinoferreras increaseinliverfibrosisinpatientswithinflammatoryboweldiseaseattheinflammatoryboweldiseasecliniccentromediconacional20denoviembre AT lorodriguezmunoz increaseinliverfibrosisinpatientswithinflammatoryboweldiseaseattheinflammatoryboweldiseasecliniccentromediconacional20denoviembre AT jglopezgomez increaseinliverfibrosisinpatientswithinflammatoryboweldiseaseattheinflammatoryboweldiseasecliniccentromediconacional20denoviembre |